Has Charles Nash received payments from drug or device companies?

Yes. Drug and device makers reported $19,446 in general payments to Charles Nash across 255 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charles Nash did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charles Nash come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charles Nash

Medical Oncology · Gainesville, GANPI 1174503585

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Astrazeneca AB at 56.9% of the total. Reporting peaked in 2019 at $12,906 and has fallen 78.7% since, to $2,747 in 2025.

$19,446in general payments, 2019–2025

Across 255 payments — averaging $76.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca AB$11K
Regeneron$3K
E.r. Squibb & Sons, L.L.C.$569
Novartis$436
Incyte Corporation$332
Merck$308
plus $4K from 41 others

$262,024in research payments, 2019–2025

Across 32 payments — averaging $8188.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$105K
Astrazeneca UK Limited$98K
Amgen$47K
Novartis$13K
Merck$96

What the payments were for

Consulting fees$2,58813%
Travel & lodging$10,93156%
Food & beverage$5,66229%
Education$2651%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca AB	6	$11,064
Regeneron	2	$2,726
E.r. Squibb & Sons, L.L.C.	18	$569
Novartis	24	$436
Incyte Corporation	10	$332
Merck	19	$308
Octapharma USA, Inc.	3	$285
AbbVie	11	$278
Seagen Inc.	8	$266
Genentech USA, Inc.	14	$263
Exelixis Inc.	10	$238
Amgen	10	$216
AstraZeneca(2 entities)	6	$192
Pfizer	15	$172
Jazz Pharmaceuticals Inc.	4	$171
GSK	4	$166
Sanofi	4	$159
Daiichi Sankyo Inc.	8	$148
Pharmacyclics LLC, An Abbvie Company	8	$132
Eisai Inc.	5	$104
Astellas Pharma US Inc	5	$102
Lilly USA, LLC	7	$95
Siemens Medical Solutions USA, Inc.	1	$85
Array Biopharma Inc	5	$82
Johnson & Johnson	5	$80
Deciphera Pharmaceuticals Inc.	3	$80
Blueprint Medicines Corporation	4	$74
Regeneron Healthcare Solutions, Inc.	3	$70
EMD Serono, Inc.	4	$63
Rigel Pharmaceuticals, Inc.	3	$60
Epizyme, Inc.	3	$51
Coherus Oncology, Inc.	3	$46
Tersera Therapeutics LLC	2	$44
Bristol Myers Squibb	2	$44
Gilead(2 entities)	3	$41
Bayer	2	$35
Boehringer Ingelheim	1	$23
Karyopharm Therapeutics Inc.	1	$20
Varian Medical Systems, Inc.	1	$20
Morphosys, US Inc.	1	$19
Beigene USA, Inc.	1	$18
Tolmar Pharmaceuticals, Inc.	1	$15
Puma Biotechnology, Inc.	1	$14
Acrotech Biopharma Inc.	1	$14
Shire North American Group Inc	1	$12
Helsinn Therapeutics (U.S.), Inc.	1	$11
Clovis Oncology, Inc.	1	$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,446 in reported general payments places this provider in the 70th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Other medical oncology in Gainesville

Andrew JohnsonGainesville$22K
Venumadhav KotlaGainesville$18K
Yamin SunGainesville$17K
Shravanti MacherlaGainesville$14K
Timothy CareyGainesville$14K
Devi SampatGainesville$13K
Jennifer AndersonGainesville$12K
Richard LociceroGainesville$9K
Nancy SteadGainesville$2K
Samir KhleifAugusta$337K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →